RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA
Trial details
- Registry ID
- NCT06146101
- Drugs studied
- Acetazolamide, Dronabinol, IHL-42X (Optimal Dose), IHL-42X High Dose and 1 more
TrialRedline tracks 3 clinical trials sponsored by Incannex Healthcare Ltd: 1 Phase 2 / 3, 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSANCT06146101 | Acetazolamide, Dronabinol, IHL-42X (Optimal Dose), IHL-42X High Dose and 1 more | Completed | 2025-05-20Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.NCT07635563 | IHL-42X: 2.5 mg dronabinol + 125 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 250 mg acetazolamide, IHL-42X: 2.5 mg dronabinol + 375 mg acetazolamide, IHL-42X: 5 mg dronabinol + 125 mg acetazolamide and 5 more | Recruiting | 2027-04Estimated |
| Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid ArthritisNCT05942911 | Cannabidiol, Hydroxychloroquine, IHL-675A | Terminated | 2024-10-28Actual |
Names as written in the registry records.
Before: Not yet recruiting. After: Recruiting.
NCT06146101 · Incannex Healthcare Ltd
Before: Estimated. After: Actual.
Before: 560 participants (planned). After: 121 participants (actual).
Before: Estimated. After: Actual.
Before: Dec 2026. After: 20 May 2025.
Before: Active not recruiting. After: Completed.
NCT05942911 · Incannex Healthcare Ltd
Before: Suspended. After: Terminated.